Clascoterone and MK-2866 Interaction

Monitor
Mechanism-based 51% confidence

Clascoterone and MK-2866 have an interaction requiring monitoring for interaction with 51% confidence. Both Clascoterone and MK-2866 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. These compounds primarily affect different organ systems.

Compound Profiles

Clascoterone

Topical Androgen Receptor Inhibitor | Acne & Hair Loss

Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target tissues -- sebaceous glands (for acne) and dermal papilla cells of hair follicles (for alopecia).

Half-life: Short topical (local action; rapidly metabolized to cortexolone) Typical dose: Acne: 1% cream 2x/day | Hair loss: 7.5% solution once daily hair loss, skin
androgen receptorngf androgenicteratogenic
View full profile

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Skin
low

Shared Safety Flags

2x 2 androgenic compounds (Clascoterone, MK-2866). Additive androgenic load — increased risk of hair loss, acne, prostate effects.

Frequently Asked Questions

Can I take Clascoterone with MK-2866?

Yes, but with caution. Both Clascoterone and MK-2866 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. Regular monitoring is advised.

Is Clascoterone and MK-2866 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic. Monitor accordingly.

What are the interactions between Clascoterone and MK-2866?

Both Clascoterone and MK-2866 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time Clascoterone and MK-2866?

Clascoterone has a half-life of Short topical (local action; rapidly metabolized to cortexolone) and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Clascoterone vs MK-2866

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.